Partnership for Part D Access
  • Home
  • About Us
    • Who We Are
    • Patient Communities
    • Our Leadership
  • The Issue
    • Six Protected Classes
    • History
  • Resources
  • Newsroom
  • Stakeholder Voices
  • Contact Us
  • Home
  • About Us
    • Who We Are
    • Patient Communities
    • Our Leadership
  • The Issue
    • Six Protected Classes
    • History
  • Resources
  • Newsroom
  • Stakeholder Voices
  • Contact Us

Newsroom​ 

Patient Advocates Commend CMS for Maintaining Medicare’s Six Protected Classes Policy

5/16/2019

1 Comment

 
As designed by Congress, Medicare’s six protected classes policy guarantees access to treatments for Medicare patients with the most complex conditions, including cancer, HIV/AIDS, mental health conditions, epilepsy, organ transplants, and Parkinson’s
Picture
​Washington D.C. — The Partnership for Part D Access, a broad-based coalition of health care stakeholders including over 20 diverse patient advocacy organizations, commended the Centers for Medicare and Medicaid Services (CMS) for not finalizing a proposal that would have substantially weakened Medicare’s six protected classes policy. 

Medicines in the six protected classes treat serious health conditions, and among these vulnerable beneficiaries — the frail, disabled or those with multiple chronic conditions — many medicines are not interchangeable. Seemingly similar patients often respond differently to the same drug: while one patient will respond well, a similar patient will have a suboptimal response, or worse. Further, drugs in the same class often have different side effects, and patients are often better suited to one particular drug over another.
 
“Medicare beneficiaries with the most complex, chronic conditions are breathing a sigh of relief,” said Chuck Ingoglia, Sr. Vice President of Public Policy and Practice Improvement at the National Council for Behavioral Health, who serves as Executive Director of the Partnership for Part D Access. “This rule cements Medicare’s protected classes policy as an essential patient safeguard in Medicare’s prescription drug program.”
 
Today’s decision was bolstered by the support of over 120 Members of Congress, including key leaders on health care committees of jurisdiction:
 
  • At a recent hearing of the Energy & Commerce Committee, four key members of the committee raised concerns with the proposal — including Ranking Member Greg Walden (R-OR) and Health Subcommittee Chair Anna Eshoo (D-CA);
  • Nineteen Energy & Commerce and Ways & Means Committee Democrats sent a letter to HHS;
  • Fourteen bipartisan Senators sent a letter to CMS; 
  • Seventy-three House Members sent a letter to HHS; and
  • Thirty-nine members of the Congressional Mental Health Caucus sent a letter to HHS. 
1 Comment
jerry miller link
12/23/2019 02:08:40 pm

It is great news that the protected class of drugs are going to stay but the law didn't go far enough. the formulary for my insurance doesn't have the brand Dilantin. On the list. As every body knows switching from brand to generic is very dangerous. Some people have no probems but other have verry dangerous problems.I know of two that died because they were swithched from brand dilantin to generic. Could you please reconsider and require that brand seizers meds be included on a formulary.

Reply



Leave a Reply.

    Author

    Write something about yourself. No need to be fancy, just an overview.

    Archives

    September 2022
    November 2021
    March 2021
    February 2021
    January 2021
    November 2020
    January 2020
    July 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    April 2018
    March 2018
    September 2017
    May 2017
    April 2017
    November 2016
    July 2016

    Categories

    All

    RSS Feed

Learn more

About Us
Patient Communities
​Issues
​Background

What's New?

​Newsroom
Resources
​

Contact

Contact Us
© COPYRIGHT 2018. ALL RIGHTS RESERVED.